Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Extended-spectrum β-lactamase (ESBL) and carbapenemase-producing Enterobacteriaceae (CPE) are among the major threats to global health because of their encoded protection against key antibiotics.

Methods: A comparative cross-sectional study was conducted among oncology and non-oncology patient groups (1:1; n = 214) on a consecutive sampling approach. Stool or rectal swab was collected from June 2021 to November 2021 and screened for ESBL-PE and CPE using ChromID-ESBL media. Confirmation for the enzymes was made by using combination disc and modified carbapenem inactivation methods, respectively. Disk diffusion method was used to determine antimicrobial susceptibility testing following the recommendations of CLSI 2022. SPSS software version 23 was used for data analysis.

Results: Fecal carriage prevalence of ESBL-PE was found in 90 (84.1%) of oncology participants and in 77 (71.9%) of non-oncology patients (p = 0.032). Escherichia coli was the most common ESBL-PE isolate in 82 (62.5%) and 68 (88.3%) of oncology and non-oncology patients, followed by Klebsiella oxytoca [15 (11.5%) versus 6 (7.8%)], respectively. Out of the total ESBL-PE isolates from both oncology and non-oncology patient groups, the maximum level of resistance was observed against ciprofloxacin 177 (86.3%), trimethoprim-sulfamethoxazole 103 (80.3%), tetracycline 97 (75.8%), whereas enhanced susceptibility was appreciated to tigecycline 200 (97.6%), meropenem 162 (79.0%), and ertapenem 145 (70.7%) with no significant difference between oncology and non-oncology group. Carbapenemase-producing isolates from oncology patients were 12 (11.2%), whereas it was 4 (3.7%) (p = 0.611) from non-oncology group. Bacterial isolates from oncology in this study showed a trend of multiple drug resistance of 113 (88.3%).

Conclusion: The results revealed alarmingly high carriage rates of ESBL and CPE among all study participants. Moreover, the isolates showed increased resistance rates to alternative drugs and had multiple antibiotic-resistant patterns. Hence, it is important to emphasize strict adherence to antimicrobial stewardship program as well as infection prevention and control practices.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625765PMC
http://dx.doi.org/10.2147/CMAR.S422376DOI Listing

Publication Analysis

Top Keywords

oncology non-oncology
20
non-oncology patients
12
isolates oncology
12
fecal carriage
8
extended-spectrum β-lactamase
8
carbapenemase-producing enterobacteriaceae
8
oncology
8
comparative cross-sectional
8
cross-sectional study
8
non-oncology patient
8

Similar Publications

ObjectiveOncology treatment regimens require increasing information technology (IT) integration in health systems to enhance delivery and safety, however, this creates a burden on medical teams and clinical pharmacists to manage. This primer introduces the University of Michigan Health Academic Medical Center's (UMH-AMC) response to this need with the Chemotherapy Orders Team (COT).SummaryThe COT includes five clinical oncology pharmacy generalists with a split full-time equivalent (FTE) appointment in COT-based activities and staffing in infusion.

View Article and Find Full Text PDF

Objective: Aim: To determine the role of autoimmune reactions on healing of BDA in patients with cholangitis.

Patients And Methods: Materials and Methods: 166 (100%) non-oncology patients with cholangitis, were divided into three groups. Group I - 92 (55.

View Article and Find Full Text PDF

Drug repurposing or drug repositioning is the process of identifying new therapeutic uses for approved or investigational drugs beyond the original treatment indication. The discovery of new drugs for cancer therapy needs this cost-effective and time-saving alternative strategy to traditional drug development for a rapid clinical translation in Phase II/III studies, especially for unmet medical needs and rare diseases. Neuroendocrine tumors (NETs) are a heterogeneous group of rare neoplasms arising from cells of the neuroendocrine system that, though often indolent, can be aggressive and metastatic.

View Article and Find Full Text PDF

Clinical Pharmacology Characterization of Bispecific T-Cell Engagers: A Summary Based on FDA Approvals.

Clin Pharmacol Ther

August 2025

Therapeutic Biologics Program, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Bispecific T-cell engagers (Bi-TCEs) have demonstrated clinical efficacy and safety, with 7 approved for hematological cancers and 2 approved for solid tumors by the US Food and Drug Administration (FDA) as of May 2025. Its intricate mechanism of action through the formation of a trimer involving Bi-TCE, T cell, and tumor cell presents challenges to clinical development requiring special strategies for multiple disciplines. This review summarizes key clinical pharmacology characterizations of these 9 FDA-approved Bi-TCEs to understand the current practice and to identify potential knowledge gaps.

View Article and Find Full Text PDF

BCR-ABL inhibitors such as imatinib and nilotinib exhibit multi-kinase activity that extends beyond oncology, offering significant potential for drug repurposing. This study aims to systematically evaluate and prioritize the repurposing potential of BCR-ABL inhibitors, particularly imatinib and nilotinib. An integrated pharmacoinformatics framework was applied to analyze seven BCR-ABL inhibitors.

View Article and Find Full Text PDF